Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM
Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.